Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Endologix Inc (ELGX)

Endologix Inc (ELGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,218
  • Shares Outstanding, K 19,172
  • Annual Sales, $ 143,370 K
  • Annual Income, $ -64,760 K
  • 60-Month Beta 0.73
  • Price/Sales 0.04
  • Price/Cash Flow N/A
  • Price/Book 0.08
Trade ELGX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.13
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 08/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.87
  • Number of Estimates 2
  • High Estimate -0.78
  • Low Estimate -0.95
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -135.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2200 unch
on 07/15/20
1.1400 -80.70%
on 06/16/20
-0.7450 (-77.20%)
since 06/15/20
3-Month
0.2200 unch
on 07/15/20
1.2600 -82.54%
on 06/09/20
-0.6221 (-73.87%)
since 04/15/20
52-Week
0.2200 unch
on 07/15/20
7.1000 -96.90%
on 07/31/19
-6.2300 (-96.59%)
since 07/15/19

Most Recent Stories

More News
Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or “the Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that, after evaluating a variety of strategic...

ELGX : 0.2200 (-23.88%)
Endologix Announces Departure of CFO and Appointment of Interim CFO

Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer...

ELGX : 0.2200 (-23.88%)
Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued...

ELGX : 0.2200 (-23.88%)
Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

Endologix ® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the...

ELGX : 0.2200 (-23.88%)
Endologix Reports First Quarter 2020 Financial Results

Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020....

ELGX : 0.2200 (-23.88%)
Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after...

ELGX : 0.2200 (-23.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 0.2999
1st Resistance Point 0.2599
Last Price 0.2200
1st Support Level 0.2000
2nd Support Level 0.1801
3rd Support Level N/A

See More

52-Week High 7.1000
Fibonacci 61.8% 4.4718
Fibonacci 50% 3.6600
Fibonacci 38.2% 2.8482
Last Price 0.2200
52-Week Low 0.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar